

Daratumumab

Cat. No.:	HY-P9915
CAS No.:	945721-28-8
Target:	CD38; ADC Antibody
Pathway:	Immunology/Inflammation; Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition ^{[1][2]} .	
In Vitro	Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells) ^[2]
	Dosage:	0.5 mg/kg
	Administration:	I.p.; 14 day after challenge with Daudi-luc cells
	Result:	Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control.

CUSTOMER VALIDATION

- Clin Cancer Res. 2023 Jun 2;CCR-23-0974.

See more customer validations on www.MedChemExpress.com

REFERENCES

-
- [1]. Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. *Oncoimmunology*. 2018;7(10):e1486948. Published 2018 Jul 23.
- [2]. de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *J Immunol*. 2011;186(3):1840-1848.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA